Anti-retroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Cribbs, Sushma K ^a   Guidot, David M ^a   Martin, Greg S ^a   Lennox, Jeffrey ^a   Brown, Lou Ann ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; GLUTATHIONE; ANTIRETROVIRUS AGENT;

AGE; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LUNG ALVEOLUS CELL; LUNG INFECTION; LUNG LAVAGE; MALE; OXIDATIVE STRESS; PATIENT SELECTION; VIRUS LOAD; ADULT; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; CROSS-SECTIONAL STUDY; EPITHELIUM; HIV INFECTIONS; LUNG ALVEOLUS; LUNG DISEASE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; RISK; STATISTICAL MODEL;

ADULT; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; BRONCHOALVEOLAR LAVAGE; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYSTEINE; EPITHELIUM; FEMALE; GLUTATHIONE; HIV INFECTIONS; HUMANS; LINEAR MODELS; LUNG DISEASES; MALE; MIDDLE AGED; ODDS RATIO; OXIDATION-REDUCTION; OXIDATIVE STRESS; PULMONARY ALVEOLI;

EID: 84895739879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088630     Document Type: Article

References (29)

1. [Anonymous] (2012) CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data-United States and 6 U.S. dependent areas-2010. HIV Surveillance Supplemental Report 2012;17(No. 3, part A).
2. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, et al. (2011) HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 183: 388-395. 201006-0836OC [pii];10.1164/rccm.201006-0836OC [doi].
3. Wallace JM, Hansen NI, Lavange L, Glassroth J, Browdy BL, et al. (1997) Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 155: 72-80. 10.1164/ajrccm.155.1.9001292 [doi]. (Pubitemid 27053144)
4. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, et al.(1995) Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 333: 845-851.
5. Jordano Q, Falco V, Almirante B, Planes AM, del VO, et al. (2004) Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 38: 1623-1628. 10.1086/420933 [doi];CID32715 [pii].
6. Caiaffa WT, Graham NM, Vlahov D (1993) Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection. Am J Epidemiol 138: 909-922. (Pubitemid 24002358)
7. Ghezzi P (2011) Role of glutathione in immunity and inflammation in the lung. Int J Gen Med 4: 105-113. 10.2147/IJGM.S15618 [doi].
8. Jones DP (2008) Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 295: C849-C868. 00283.2008 [pii];10.1152/ajpcell.00283.2008 [doi].
9. Jones DP (2006) Redefining oxidative stress. Antioxid Redox Signal 8: 1865-1879.
10. Cantin AM, North SL, Hubbard RC, Crystal RG (1987) Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol (1985) 63: 152-157.
11. Lassiter C, Fan X, Joshi PC, Jacob BA, Sutliff RL, et al. (2009) HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res Ther 6: 1.
12. Jacob BA, Porter KM, Elms SC, Cheng PY, Jones DP, et al. (2006) HIV-1-induced pulmonary oxidative and nitrosative stress: exacerbated response to endotoxin administration in HIV-1 transgenic mouse model. Am J Physiol Lung Cell Mol Physiol 291: L811-L819. (Pubitemid 44498494)
13. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, et al. (2000) Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses 16: 1929-1938. 10.1089/ 088922200750054657 [doi].
14. Aukrust P, Muller F, Svardal AM, Ueland T, Berge RK, et al. (2003) Disturbed glutathione metabolism and decreased antioxidant levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy-potential immunomodulatory effects of antioxidants. J Infect Dis 188: 232-238. JID30534 [pii];10.1086/376459 [doi].
15. Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, et al. (1997) Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A 94: 1967-1972. (Pubitemid 27113945)
16. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE (1997) Alveolar fluid glutathione is not reduced in asymptomatic HIV-seropositive subjects. Am J Respir Crit Care Med 155: 374-377. (Pubitemid 27053191)
17. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE (1997) Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest 112: 785-788. (Pubitemid 27410719)
18. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, et al. (1989) Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 2: 1294-1298. (Pubitemid 20005670)
19. Diaz PT, Wewers MD, King M, Wade J, Hart J, et al. (2004) Regional differences in emphysema scores and BAL glutathione levels in HIV-infected individuals. Chest 126: 1439-1442. 126/5/1439 [pii];10.1378/chest.126.5.1439 [doi].
20. Awodele O, Olayemi SO, Nwite JA, Adeyemo TA (2012) Investigation of the levels of oxidative stress parameters in HIV and HIV-TB co-infected patients. J Infect Dev Ctries 6: 79-85.
21. Moss M, Guidot DM, Wong-Lambertina M, Ten Hoor T, Perez RL, et al. (2000) The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. Am J Respir Crit Care Med 161: 414-419. (Pubitemid 30129446)
22. Yeh MY, Burnham EL, Moss M, Brown LA (2007) Chronic alcoholism alters systemic and pulmonary glutathione redox status. Am J Respir Crit Care Med 176: 270-276. 200611-1722OC [pii];10.1164/rccm.200611-1722OC [doi].
23. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, et al. (2003) Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 37: 1711-1717. 10.1086/379776 [doi];CID31711 [pii].
24. Droge W, Pottmeyer-Gerber C, Schmidt H, Nick S (1986) Glutathione augments the activation of cytotoxic T lymphocytes in vivo. Immunobiology 172: 151-156. (Pubitemid 16024265)
25. Cantin AM, North SL, Hubbard RC, Crystal RG (1987) Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 63: 152-157. (Pubitemid 17107139)
26. Buhl R, Jaffe HA, Holroyd KJ, Borok Z, Roum JH, et al. (1993) Activation of alveolar macrophages in asymptomatic HIV-infected individuals. J Immunol 150: 1019-1028. (Pubitemid 23133682)
27. Pacht ER, Abernathy F (1995) Prevention of intracellular adenosine triphosphate depletion after sublethal oxidant injury to rat type II alveolar epithelial cells with exogenous glutathione and N-acetylcysteine. Am J Med Sci 310: 133-137.
28. Pacheco YM, Jarrin I, Del AJ, Moreno S, Iribarren JA, et al. (2009) Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr HIV Res 7: 612-619.
29. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, et al. (2003) Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 37: 1711-1717. 10.1086/379776 [doi];CID31711 [pii].